2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Pregnant, Young Adult
PAPER

2684 Real-world unmet needs in adults with severe hemophilia A — a CHESS US analysis

Jing Voon Chen, PhD, Emily L. Waters, PhD2, Enrico Ferri Grazzi, MSc3, Katharine Batt, MD4
1 Novo Nordisk Inc., Plainsboro, New Jersey, United States
2 Novo Nordisk Inc., Plainsboro, New Jersey, United States
3 HCD Economics, Daresbury, United Kingdom, Italian Federation of Haemophilia Associations, Rome, Italy
4 Sprouts Healthcare Consulting, Raleigh, North Carolina, United States

Introduction

The introduction and ongoing approval of novel nonfactor therapies (NFTs) have changed the hemophilia treatment landscape, moving beyond conventional factor VIII (FVIII) replacement therapies. With new options available, patients may choose to switch treatments for a variety of reasons. This study evaluates treatment switching and reasons for treatment choice, adherence, reported use of FVIII replacement therapy for additional bleed protection, physical activity, and bleeding outcomes in adults with severe hemophilia A (HA).

Methods

This analysis used secondary data from the "Cost of Hemophilia: a Socioeconomic Survey US" (CHESS US), a repeated, retrospective, cross-sectional study of US adults (aged ≥18 years) diagnosed with hemophilia (with or without inhibitors). The CHESS dataset is collected through a physician-completed clinical report form and a patient-completed self-report form. Data were collected from 2023 to 2025, and only those with severe HA (FVIII <1%) were included in this analysis. Physician-reported outcomes included patient characteristics, treatment patterns, adherence, and clinical outcomes, including annualized bleed rate (ABR). Patient-reported outcomes included physical activity and use of additional FVIII replacement therapy for bleed protection. FVIII replacement therapies included standard half-life (SHL), extended half-life (EHL), and ultra-long half-life (UHL). NFT therapy comprised emicizumab. Analyses were descriptive.

Results

Of the 292 severe HA patients, 263 were on prophylaxis (NFT: 157 [54%] and FVIII: 106 [36%]). The mean age (SD) of patients receiving NFT was 33.1 (12.8) years, whereas those on FVIII prophylaxis averaged 28.5 (8.2) years. Most patients had never developed inhibitors: 76% for NFT and 84% for FVIII prophylaxis. On average, patients on NFT had 0.8 (1.7) target joints, compared with 0.5 (0.8) among patients on FVIII prophylaxis. A total of 55 patients with severe HA had a treatment class switch in the 12 months prior to data collection. Fifty-five percent of the treatment class switches were from FVIII therapies to NFT, whereas 11% were from NFT to UHL. Top drivers for choosing NFT included efficacy (50%), tolerability (27%), and product availability (23%), whereas efficacy (52%), administration frequency (35%), and product availability (26%) were the main factors for use of FVIII prophylaxis. Among patients receiving NFT prophylaxis, 44% of those on an every 4-week (Q4W) regimen transitioned from other NFT frequencies, compared with 19% on an every-week (QW) regimen and 30% on an every 2-week (Q2W) regimen, suggesting a shift towards a less burdensome schedule. Adherence was suboptimal across age groups, with lower adherence observed in the older age group: most patients aged 18-26 were fully adherent (defined as <15% of late/missed administrations), but only about 60–65% of those between 27 and 50 years old were fully adherent, and even lower adherence was observed in adults aged >50 years (<40%). Data on regimen-specific adherence indicated that 67% of patients on NFT were fully adherent, compared with 80% on FVIII prophylaxis. Most (86%) patients on NFT engaged in moderate-to-vigorous physical activity, and 65% reported FVIII replacement use for additional bleed prevention in preparation for activity or in response to events associated with potential bleeding risk. Analysis of bleeding outcomes in this population showed that 56% of patients on NFT and 41% of those on FVIII prophylaxis had one or more breakthrough bleeds per year. The mean ABR was 1.1 (1.5) among those on NFT and 0.9 (1.4) for those on FVIII prophylaxis.

Conclusion

Our analysis highlights persistent unmet needs in severe HA, as patients continue to seek alternative treatment options to optimize efficacy and reduce treatment burden. Suboptimal adherence, particularly among middle-aged and older adults, may compromise therapeutic outcomes. Use of additional FVIII treatment for preventive reasons suggests either proactive management of activity-associated bleeding risk or possible inadequacies in perceived or actual protection provided by current regimens. A patient-centered prophylaxis optimization that focuses on improved durability and convenience of protection compatible with active lifestyles, which may also improve treatment adherence, is needed. These findings highlight the need for new treatments that better meet the clinical needs of this population.

Jing Voon Chen, PhD: Novo Nordisk Inc. - Current Employment